Cargando…
Hyperbilirubinaemia in patients treated with recombinant human interleukin-2 (rIL-2)
Autores principales: | Punt, C. J., Henzen-Logmans, S. C., Bolhuis, R. L., Stoter, G. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1990
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971290/ https://www.ncbi.nlm.nih.gov/pubmed/2328219 |
Ejemplares similares
-
Prolonged continuous infusion of low-dose rIL-2.
por: Janssen, R. A., et al.
Publicado: (1994) -
Flavone acetic acid (FAA) with recombinant interleukin-2 (rIL-2) in advanced malignant melanoma. III: Cytokine studies.
por: Haworth, C., et al.
Publicado: (1993) -
Recombinant interleukin-2 (rIL-2) with flavone acetic acid (FAA) in advanced malignant melanoma: immunological studies.
por: Ghosh, A. K., et al.
Publicado: (1990) -
Recombinant interleukin-2 (rIL-2) with flavone acetic acid (FAA) in advanced malignant melanoma: a phase II study.
por: Thatcher, N., et al.
Publicado: (1990) -
Recombinant interleukin-2 (rIL-2) given intrasplenically and intravenously for advanced malignant melanoma. A phase I and II study.
por: Thatcher, N., et al.
Publicado: (1989)